NEW DELHI: Drug main Lupin on Wednesday introduced the launch of its Favipiravir drug below the model title ‘Covihalt’ for the remedy sufferers with gentle to reasonable COVID-19 signs at Rs 49 per pill in India. Favipiravir has obtained authorisation […]
Favipiravir has obtained authorisation from the Drug Controller Basic of India (DCGI) for emergency use, Lupin mentioned in a regulatory submitting.
Coronavirus outbreak: Stay updates
Its Covihalt dosage power has been developed protecting in thoughts comfort of administration, it said, including that the drug is out there as 200 mg tablets within the type of a strip of 10 tablets, and priced at Rs 49 per pill.
Lupin president – India Area Formulations (IRF) Rajeev Sibal mentioned the corporate believes that it will probably leverage its experience in managing widespread group illnesses like tuberculosis to proactively attain sufferers throughout India and guarantee entry to Covihalt via its sturdy distribution community and discipline power.
On August 4, Solar Pharmaceutical Industries had launched Favipiravir below the model title ”FluGuard” for the remedy of gentle to reasonable instances of Covid-19, at Rs 35 per pill in India.
Extra on Covid-19
Shares of Lupin have been buying and selling 0.32 per cent greater at Rs 943.70 apiece on BSE.